

REMARKS

In response to the June 10, 2004 Notice to Comply with Sequence Listing Requirements, Applicants submit herewith an initial computer readable form (CFR) copy of the "Sequence Listing"; an initial paper copy of the "Sequence Listing"; a statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 37 C.F.R. §§ 1.821-1.825; and replacement figures 12-14 in compliance with 37 C.F.R. §§ 1.84.

The specification has been amended to insert replacement drawings in compliance with 37 C.F.R. §§ 1.84, and to insert the sequence listing.

The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 18989-033. Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ingrid A. Beattie, Reg. No.42,306
Cynthia A. Kozakiewicz, Reg. No.42,764
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Dated: October 7, 2004



		Section 1						
		(1)	1	10	20	30	40	52
ApoB 1-269	(1)	-----	MDPPRPALLALLA	P	LLLLLLLAGAR	EEE	LE	
CD1d human	(1)	MGCLLFLLWALLQAWGSAEVPQRLFPLRCLQ	S	FANSSWTRTD	LAW	GE		

		Section 2						
		(53)	53	60	70	80	90	104
ApoB 1-269	(34)	NV	LVCPKD	TRF	HL	K	YN-----	YEAE--S-SSGVPGTA
CD1d human	(53)	LQ	HSWSND	DTV	SL	P	QGTFSQQWETLQHIFRVYRSSFTRDVK	FAK

		Section 3						
		(105)	105	110	120	130	140	156
ApoB 1-269	(73)	ATR	NCK	ELEV	QQLCSFILK--	S-----	QCTLKEVYGFNP	
CD1d human	(105)	MLR	SYP	ELQVSAGCEVHPGNA	NNFFHVA	FQGKDILSFQGTSWEPTQEAP		

		Section 4					
		(157)	157	170	180	190	208
ApoB 1-269	(108)	EGKALLKKTNS	E	AAAMSR	ELKLAIPEGKQVFLYPEKDEPTYILNKR	G	
CD1d human	(157)	LWVNLAIQVLNQ	K	TRETVQ	LLNGTC	PQFVSGLLLESGKSE----	LKKQV

		Section 5						
		(209)	209	220	230	240	250	260
ApoB 1-269	(160)	IISALLVPPE	EEAKQ	LF	DTVYGNCS	THFTVKTR	GN-----	A-
CD1d human	(204)	KPKAWLSRGP	PGPGR	LL	CHVSGFY	PKPVWVKWM	GEQEQQGTQPGD	LP

		Section 6						
		(261)	261	270	280	290	300	312
ApoB 1-269	(201)	-----T-----	STERDLGQCDR	FKPIRTGISP	ALIKGM	RPLSTLI	S	
CD1d human	(256)	NADETWYLRATL	VAGEAAGL	SCRVKHSSLEGQD	VLYWGG	YTSMGLI	L	

		Section 7				
		(313)	313	320	330	343
ApoB 1-269	(242)	QS-----	CQ	TLDAKRKHVAE	CKEQ	
CD1d human	(308)	VLACLLFLLIVG	TSRFRQ	TSYQ	L---	

SEQ ID NO: 11
 SEQ ID NO: 12

Fig. 12



		Section 1					
		(1) 1	10	20	30	40	52
ApoB 512-721	(1)	-----K					
CD1d human	(1)	MGCLLFLLLWALLQAWGSAEVPQRLFPLRCLQISSFANSSWTRTDGLAWLGE					
		Section 2					
		(53) 53	60	70	80	90	104
ApoB 512-721	(2)	CVQS	KPSLMIQKA	QALRKMEPKDKDQEVLLQTFLDDASPGD	R	AA	LM
CD1d human	(53)	LQTH	WSNDSDTVR	KPWSQGTFS	DQWETLQHI	FRVYRSSFT	DKEAK
		Section 3					
		(105) 105	110	120	130	140	156
ApoB 512-721	(54)	RS--PSQAD	NKIVQ	LPWEQNE	-----QVKN		VAHIAN
CD1d human	(105)	RLSYPLELQ	SAGCE	HPGNASNNFFH	VAFQGDILSFQGT	S	EPQEAP
		Section 4					
		(157) 157	170	180	190	208	
ApoB 512-721	(89)	LNSEE	D	QDLKKLV	EA	KESQLPTVMDFRKFSRN	-----YQLYKSVL
CD1d human	(157)	WVNLA	Q	LNQDKWT	ET	QWLLNGT	CPQFVSGLLESGKSELKKQVKPKW
		Section 5					
		(209) 209	220	230	240	250	260
ApoB 512-721	(135)	PSLDP	S	KIEGNL	FDPNN	LPK--ESM	TTLTAFGFASD
CD1d human	(209)	LSRGP	P	PGRLLL	CHVSG	YPKPVVVKW	GEQEQQGTQPD
		Section 6					
		(261) 261	270	280	290	300	312
ApoB 512-721	(184)	KGFEPTL	A	FGKQ	-----FFP		SVNKALYW
CD1d human	(261)	WYLRATL	V	AGEA	GLSCRVKHSSL	GQDIVLYW	GGSYTSMGLIALAVLAC
		Section 7					
		(313) 313	320	335			
ApoB 512-721	(211)	-----					
CD1d human	(313)	LLFLLIVGFTSRFRQTSYQGV					

SEQ ID NO: 13

SEQ ID NO: 15

SEQ ID NO: 13
SEQ ID NO: 15

Fig. 13



		Section 1					
		(1) 1	10	20	30	40	52
ApoB 270-570	(1)	-----FSYNNKYGMVAQVTQTLKLEDTPKINSRFFGEGT					KMGLAEST
CD1d human	(1)	MGCLLFLLLWALLQAWGSAEVPQRLFPLRCLQISSFANSSWT					TDGLALGE
		Section 2					
		(53) 53	60	70	80	90	104
ApoB 270-570	(45)	KSTSPPK	AEAV	LQELKKLTIS	QIQRA	LPN	VTELRGLSDEAVTS
CD1d human	(53)	LQTHSWS	DSDT	LKPWSQGTF	QWETL	HIF	YRSSFTRDVKEFAK
		Section 3					
		(105) 105	110	120	130	140	156
ApoB 270-570	(97)	LPQLIE	SSP	LQALVQCG	PQCSTHI	QLK	VHANPLLIDVVTYLVAL
CD1d human	(105)	LRLSYP	ELQ	AGCEVHPG	ASNNFFH	AQG	DILSFQGTSWEPTQEAP
		Section 4					
		(157) 157	170	180	190	208	
ApoB 270-570	(149)	PEPSAQQ	REIFNMAR	QRSRATLYALSHAVNNYHK	NP	GTQEL	DIAN
CD1d human	(157)	WVNLAIQ	LNQDKWTR	TVQWLLNGT	CPQFVSGLLE	GK	ELKKQKPKA
		Section 5					
		(209) 209	220	230	240	250	260
ApoB 270-570	(201)	LMEQIQDD	-----C	GDEDYTYL	LR	IGNMGQTMEQLTPELKS	ILK
CD1d human	(209)	LSRGPSPGPGRLLLVCHV		GFYPKPVW	KW	RGEQEQQGTQPGDILPN	DET
		Section 6					
		(261) 261	270	280	290	300	312
ApoB 270-570	(244)	CVQSTKPS	IQKAAIQ	LRKMEPKDKDQ		LQTFLDDASPGDKRLAAYLM	
CD1d human	(261)	WYLRATLD	AGEAAGL	CRVKHSSLEGO		LYWGGSYTSMGLIALAVLAC	
		Section 7					
		(313) 313	320	335			
ApoB 270-570	(296)	L	RSPS	-----			
CD1d human	(313)	L	FLLIVGFTSRFKRQTSYQGV	L			

SEQ ID NO: 14
SEQ ID NO: 16

Fig. 14